Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Investor Presentation (April 2015)

21 slides from Sucampo Pharmaceuticals's investor presentation, Apr 14, 2015

  1. Slide 1: Sucampo Pharmaceuticals, Inc.

    Sucampo Pharmaceuticals, Inc. Peter Greenleaf CEO 3 SUCAMPO The Science of Innovation

  2. Slide 2: Forward-Looking Statements

    -Looking Statements This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ material

  3. Slide 3: Sucampo Overview

    Sucampo Overview = Sucampo is a global biopharmaceutical company built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients = Proven track record of successful pharmaceutical product development and approvals = Deep management bench with prove

  4. Slide 4: Investment Highlights

    Investment Highlights = Multiple levers available to drive sustainable long term growth = Well-defined lifecycle management strategy maximizes franchise value $ sucampo 4 The Science of Innovation

  5. Slide 5: Clear Strategy to Methodically Build a Leading Bio/Pharma Company

    Clear Strategy to Methodically Build a Leading Bio/Pharma.Company Revenue & Market Value SS = Focus efforts and strengthen overall = Address capital structure + Diversify investor base capabilities + Team = Continue to * Development capability strengthen capability in development = Secure and grow A

  6. Slide 6: Expanded Management Team with Considerable Experience in Product Development and Commercialization

    @ tiistogenics [hdl Setomfotrmen AstraZeneca 2 Meine € centocor Bristol-Myers Squibb ial Zyngenia rn ESBATech Expanded cy g Wh novarris Management CY micr@met Team with 5 Considerable Astrazeneca? | M | Vivus eh batts aasarie in Product 0 - Development and Geamag id mawcer aaa C= commercialization D

  7. Slide 7: AMITIZA (lubiprostone)

    Ses" amitiza lubiprostone e > SUCAMPO i The Science of Innovation

  8. Slide 8: Unique and Highly-Differentiated Product

    Unique and Highly-DifferentiatedhProduct = Most expansive label in constipation market: 3 indications, 3 patient types * CIC: Chronic Idiopathic Constipation * IBS-C: Irritable Bowel Syndrome with Constipation * OIC: Opioid Induced Constipation in Adults (non-cancer) = Most experienced product: over

  9. Slide 9: Constipation market category share

    48.2 MTRX Sorbitol, __ Bulk Fiver (Citrucel, Generic 4 mineral oli [~ Benefiber) Linaclotide \ Fleet Enemas (1%) f 7] Other ie 3% AMITIZA, Miralax, PEGs Reaiited ‘Stimulant Laxatives Brand (Ex-Lax, Dulcoiaxy Category thru Dec 2014 Benty r osmiPrep, PES pops Sort mine BS Premrayevacmts ie "] wy 58520

  10. Slide 10: Growth is Evidence of Compelling Value Proposition

    yth is Evidence of Compelling Value Proposition 2014 total prescriptions were 1.3M; all-time yearly high 1,350 00 4,400,000 ToL ean 1,300,000 1,200,000 1,250,000 | 1,900,000 | 4 2 | 2 = 1,200,000 | = 00000 3 b a 1,150,000 E coo.000 11504 | i 489,543 4 100000 +} 40000 | 1950 00 | 200,000 | 7652 1,000

  11. Slide 11: Takeda - global partnership

    Y Takeda - global partnership US. ¥ Yearly Increases + Canada v EU 7 Takeda Y Gross-to-net cap aaa “Teverue spiton ‘fer Sueampe + ROW Y Underpenetrated bere markets with — lubiprostone, ¥ unsatisfied patients ine! LOM Milan V Expanded Takeda * depen agreement Y Agreement Y Physician Targeting with P

  12. Slide 12: New Market Opportunities

    New Market Opportunities Global prevalence of constipation disorders ranges from 5-18% secsensonsonsensnassasaas asi { : no ee, i EU." i f" Canada i cic i i ClCandoic i i 4 NDA decision i “seunsensnnsansansanennennsnnsane® . 5 2H:15 - "Nanensennatenmeannneenatnna ( \ : Se renee. | Switzertand | H us

  13. Slide 13: AMITIZA Life Cycle Management

    AMITIZA Life Cycle Management Expand AMITIZA franchise through new formulation and new indication 1. New Formulation + Alternate formulation for additional adult and pediatric patients who cannot tolerate capsules, or naso-gastric tube fed patients + Incremental opportunity to address the roughly 40

  14. Slide 14: $ sucampo “

    $ sucampo “ The Science of Innovation

  15. Slide 15: At-A-Glance: Sucampo Pipeline

    At-A-Glance: Sucampo Pipeline | cunicatrocus | FOCUS STAGE OF CLINICAL DEVELOPMENT TIMELINE TARGETS Lubiprostone — Pediatric Functional t ‘pen-Label Constipation (6 years-17 years) Raper FeI—2H 215 Lena 2016 Lifecycle Management Lubiprostone — Alternate Formulation — Pediatric Functional Constipatio

  16. Slide 16: Supplementing Existing Pipeline

    Supplementing Existing Pipeline 9O0000 Commenced assessment of external programs Complement existing product pipeline Leverage current skills and experience of Sucampo Therapeutic areas Platform- and technology- agnostic Orphan and specialist products $ sucampo 8 The Science of Innovation

  17. Slide 17: $ sucampo "7

    $ sucampo "7 The Science of Innovation

  18. Slide 18: Cash & Equivalents $110.0M

    Cash & Equivalents $110.0M Notes Payable $25.8M Total Revenue $37.8M. Net Income $9.3M EPS $0.21 AMITIZA U.S. Net Sales (as reported by Takeda for royalty calculation purposes): $91.1M Total Revenue $115.5M Net Income, excluding special items $17.9M EPS, excluding special items. $0.40 AMITIZA U.S. N

  19. Slide 19: Upcoming Milestones

    Upcoming Milestones Global partnership agreement for AMITIZA, Undated on AMITIZA altemate formulation and PFC development Filed AMITIZA (CIC and OIC) for approval in Canada Initiated MRP to secure approval for AMITIZA (CIC) in additional European markets Dacision made on ion channel activator progra

  20. Slide 20: Investment Highlights

    Investment Highlights = Lead product with differentiated profile in an attractive market with a large unmet need = Blue chip partnerships provide global reach and drive outsized revenue growth = Multiple levers available to drive sustainable long term growth = Robust product pipeline that will build

  21. Slide 21: Sucampo

    ¢ ‘ $sucampo The Science of Innovation

Sucampo Pharmaceuticals — Investor Presentation (April 2015) on 6ix